The World Health Organization (WHO) estimates that 20 million hepatitis E virus (HEV) infections occur worldwide each year ([@B1]). HEV infection is endemic to many low-income countries and is recognized as an emerging infection in developed regions (e.g., Europe). HEV usually causes self-limiting hepatitis but occasionally leads to fulminant liver failure and, in immunosuppressed patients, chronic HEV infection. Furthermore, the frequent detection of HEV-specific antibodies in the sera of people with no history of hepatitis indicates that mild and subclinical courses of HEV infection are also common ([@B2]). The virus is mainly transmitted via the fecal--oral route, and waterborne epidemics due to fecally contaminated drinking water are typical for hepatitis E in developing countries, including those in Latin America and the Caribbean (LAC) ([@B3]--[@B4]). In addition, the zoonotic potential of HEV is recognized, with pigs being the main animal reservoir for two of the human-pathogenic HEV genotypes. Meat prepared from infected animals or other food contaminated with virus-containing excretions may therefore represent sources of HEV infection ([@B5]). An HEV vaccine was licensed in China in 2011 but is not available worldwide.

HEV includes at least four human-pathogenic genotypes (HEV-G1, -G2, -G3, and -G4) and several subtypes ([@B6]). HEV-G1 is hyperendemic in Asia and Africa and frequently causes large outbreaks of acute hepatitis ([@B7]). This genotype has also been detected in Cuba, Uruguay, and Venezuela ([@B3]--[@B4]). HEV-G2 has been reported in Mexico and some countries in Africa. HEV-G3 and -G4 are zoonotic viruses and have been detected in humans and animals (mainly pigs). HEV-G3 is detected in many countries of the world and is the genotype most frequently found in South America. HEV-G4 is almost exclusively restricted to Asia ([@B3], [@B4], [@B7]). HEV genotypes and reservoirs from nine LAC countries (Argentina, Bolivia, Brazil, Colombia, Costa Rica, Cuba, Mexico, Uruguay, Venezuela) ([@B8]--[@B19]) are shown in [Table 1](#t1){ref-type="table"}. Specific clinical manifestations of HEV infection have been tentatively associated with distinct genotypes; for example, HEV-G1 is related to fulminant acute hepatitis in pregnancy, whereas HEV-G3 is associated with chronic liver disease in immunosuppressed patients ([@B2], [@B7]).

###### Reported HEV genotypes and host/source of infection in LAC

  Country      HEV host/source   HEV genotype                       Source
  ------------ ----------------- ---------------------------------- ------------------
  Argentina    Environment       3                                  ([@B3])
               Human             3                                  ([@B4])
               Swine             3                                  ([@B4])
  Bolivia      Human             3                                  ([@B4])
               Swine             3                                  ([@B4])
  Brazil       Human             3                                  ([@B4])
               Swine             3                                  ([@B4], [@B8])
  Colombia     Environment       3                                  ([@B9])
               Human             3                                  ([@B10])
               Swine             3                                  ([@B11], [@B12])
  Costa Rica   Swine             3                                  ([@B3])
  Cuba         Dolphin           3[a](#TFN1){ref-type="table-fn"}   ([@B13])
               Human             1 and 3                            ([@B14])
               Swine             3                                  ([@B15])
  Mexico       Human             2                                  ([@B16])
               Swine             3                                  ([@B3])
  Uruguay      Human             1 and 3                            ([@B17], [@B18])
  Venezuela    Human             1 and 3                            ([@B19])

Source: Compiled by the authors based on published data.

Provisionally classified as genotype 3.

The symposium "Epidemiology of HEV infection and associated Immune Response" was held at the Universidad de Guadalajara, Mexico, on 14 June 2017, to define the status of research on HEV infection in Cuba, Mexico, and Uruguay compared to the situation in Germany. The scientists attending the meeting 1) identified specific research gaps in understanding HEV transmission and the resulting impact on development of the disease in these three countries, and 2) proposed specific recommendations for implementing standardized serologic and molecular diagnostic methods and epidemiologic, basic, and applied research aimed to develop prevention and handling strategies for this infection. Associated comorbidities in the three LAC countries were also discussed.

CURRENT STATUS OF HEV RESEARCH AND MANAGEMENT IN GERMANY VERSUS THREE LAC COUNTRIES: CUBA, MEXICO, AND URUGUAY
==============================================================================================================

HEV in Germany: an example of the current situation in Europe
-------------------------------------------------------------

During the last decade, interest in HEV infections has been largely increasing in Europe, mainly driven by the identification of animal reservoirs for HEV in European countries ([@B20]). A comparison of the number of HEV-related scientific reports published in Europe versus LAC countries illustrates the overall increase in research activity as well as the differences between the two regions ([Figure 1](#f1){ref-type="fig"}). In Germany, hepatitis E has been a notifiable disease since 2001. An increase in hepatitis E cases has been identified in recent years, with 51 cases in 2006 and 1 993 cases in 2016. Improved awareness and diagnosis are suspected as reasons for the increase. Detailed molecular investigations on HEV transmission identified 1) pigs and wild boars as the main HEV reservoirs in Germany and 2) several common HEV-G3 subtypes circulating in animals and humans ([@B21]). HEV-RNA was also detected in meat products. Currently, cell culture systems are being developed and used for the determination of HEV stability. These cell culture systems will 1) enable risk assessments of distinct food products as sources of infection and 2) identify reliable inactivation methods ([@B22]). Other activities focus on further harmonization of HEV detection methods in humans, animals, and food as well as therapeutic methods for treating acute and chronic disease. Screening of blood banks for HEV for prevention of transfusion-transmitted infections is also being discussed. Information for hygienic and safe preparation of food and specific suggestions for risk groups have been made available for the public.
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HEV in Cuba: epidemiology and molecular characterization
--------------------------------------------------------

HEV infection is a significant cause of sporadic cases and outbreaks of acute viral hepatitis in Cuba, where the prevalence of infection ranges from 5.3% to 10% in open populations ([@B23]). Coinfection of HEV with ­hepatitis A virus (HAV), hepatitis B virus (HBV), and hepatitis C virus (HCV) has been serologically identified in Cuba, but HEV-HAV is the most common combination, reflecting the similar transmission routes of these viruses ([@B24]). High detection rates of anti-HEV antibodies (35.8%) are described for persons who work in contact with swine. Age and time spent working on farms are risk factors associated with HEV infection in swine workers. HEV-G1a and HEV-G1d have been repeatedly identified in the Cuban human population. In addition, HEV-G3a has been detected in pigs and in subclinically infected farm workers ([@B15]). Phylogenetic analysis shows that human and swine HEV strains are closely related, with 94%--99% nucleotide sequence identity. Furthermore, seroconversion and HEV-G3b have been recently identified in bottlenose dolphins (*Tursiops truncates*) in Cuba ([@B13]), but the clinical relevance of this infection requires further investigation. Thus, zoonotic HEV-G3 and epidemic HEV-G1 strains seem to co-circulate in Cuba.

Genetic variability of HEV in Mexico
------------------------------------

HEV-G2 was first described in an outbreak in Mexico in the late 1980s and continues to be an enigma for virology. Thirty-one years after this outbreak, no new reports of HEV-G2 in Mexico have been published, and no other data on this genotype are available from government or public sources. More recent investigations in Mexico have identified HEV-G3 infections in animals ([@B3]). A high seroprevalence of HEV in samples from cirrhotic patients with no other etiologic agent present has been reported ([@B25]), suggesting an HEV role in the development of chronic liver illness. Seroconversion has also been found in deer ([@B26]) and farmed pigs intended for human consumption ([@B27]). Based on these findings, the expected seroprevalence and risk of HEV infection in Mexico is rather high, as reported in HAV-HEV coinfected children ([@B28]). Preliminary estimates for the general population suggesting that HEV causes unnoticed infections in Mexico support this hypothesis, indicating a potential public health concern that is not sufficiently documented.

HEV in the environment, humans, and swine in Uruguay
----------------------------------------------------

HEV was first associated with acute clinical hepatitis in Uruguay during 2009 and 2010. Since then, the number of cases has increased. Molecular epidemiology of HEV suggests that HEV-G3 is most prevalent among the human population, but epidemic HEV-G1 strains have also been reported ([@B17], [@B18]). Phylodynamic and evolutionary studies on HEV-G3 isolates have shown that HEV infection in Uruguay is an emergent process. All detected HEV-G3 strains belong to a European lineage and have a common ancestor dating to approximately 15 years ago ([@B29]). Seroprevalence data suggest that HEV is widely distributed among swine and wild boars in Uruguay. These reservoirs constitute a potential risk for zoonotic transmission of HEV. In addition, HEV-G1 has been detected in water matrices from suburban areas with poor sanitary conditions in Uruguay. However, the exact role of this source of contamination and its impact on human health remain largely unknown.

IMMUNOPATHOGENESIS OF HEV
=========================

Given that HEV is a noncytopathic virus, the liver damage resulting from the infection is not directly associated with the virus replication. Liver damage is likely produced by the virus-specific, cell-mediated immune response to infected hepatocytes. Significant progress has been made toward understanding the immunopathogenesis of HEV in cases from European and North American countries and in those from outbreaks in Asia. In contrast, studies in LAC populations are scarce. More studies in these populations are needed because of the ethnic complexity of the LAC region, which may affect clinical outcomes and treatment strategies for HEV infection. Given the availability of an HEV vaccine in China, understanding the determinants for susceptibility and resistance to infection is imperative in different regions throughout the world.

IDENTIFIED RESEARCH GAPS AND RECOMMENDATIONS
============================================

HEV infection is common in LAC countries but has not been completely characterized. The following research gaps and recommendations were identified at the symposium in Mexico, based on reported research experiences from Cuba, Mexico, and Uruguay:

1.  Research gap: The burden of diseases caused by HEV infection is not known.

    Recommendation: Implementation of a notification system for HEV cases to help estimate the impact of infections on human health.

2.  Research gap: Detection methods for HEV are not harmonized, and high inter-laboratory variability is expected.

    Recommendation: Since 2009, an international WHO standard for HEV ribonucleic acid (RNA) has been available for use in nucleic acid amplification technique (NAT)-based assays. Validation of diagnostic tests in laboratories in the LAC region should be performed using this standard in order to harmonize methods and enable comparison of epidemiologic data.

3.  Research gap: Genetic characterization of circulating HEV strains is not yet routinely established.

    Recommendation: Analysis of the genetic HEV variability in the general population, high-risk populations, and animal reservoirs is necessary to identify virus transmission pathways and epidemiologic presentations.

4.  Research gap: The consequences of acute HEV infection for specific risk groups have not been investigated.

    Recommendation: Studies are needed to determine the risk of acute infection in children and pregnant women and the impact of the HAV-HEV coinfection in the LAC region. The effects of high pork meat consumption and deficient sanitary conditions need to be determined. Similarly, investigations on acute HEV infection as a risk factor for exacerbation of liver damage, within the context of chronic liver diseases commonly found in Cuba, Mexico, and Uruguay (e.g., fatty liver disease, obesity, chronic HBV and HCV infection, and high alcohol consumption), should be assessed.

5.  Research gap: The mechanisms involved in chronic liver damage (fibrosis and cirrhosis) in HEV-infected immunosuppressed patients (e.g., organ transplant patients, patients receiving chemotherapy, and HIV patients) are not known so far. In addition, management strategies for patients with liver damage due to chronic HEV infection are not harmonized.

    Recommendation: Further studies to uncover the mechanisms of liver damage in chronically HEV-infected patients are required.

6.  Research gap: The role of genetic factors in HEV-infected patients, which may influence immune response, disease outcome, and response to therapy, has not been extensively studied.

    Recommendation: Investigations on HEV-related immunopathogenesis and the influence of host genetic factors on HEV infection are required.

7.  Research gap: The risk of blood banks as a source of HEV infection has not been analyzed.

    Recommendation: Studies assessing HEV contamination rates in blood donations and blood products should be initiated.

8.  Research gap: The detection of HEV in multiple animal reservoirs has been demonstrated, but the relative importance of animals as a source of human infection is not known.

    Recommendation: Investigations on transmission chains from animal reservoirs to humans, including the food-borne route, should be initiated.

9.  Research gap: The presence of HEV in the wastewater of cities in Uruguay has been demonstrated, although the importance of this type of environmental contamination for human hepatitis E cases remains unknown.

    Recommendation: Sources of HEV contamination of the environment should be identified.

10. Research gap: The systems currently available for propagation of HEV are unsophisticated, inefficient, and often poorly reproducible.

    Recommendation: A reliable cell culture system would help in the investigation of 1) HEV inactivation, 2) HEV drug discovery, and 3) immune defense strategies against HEV. Efforts to improve cell culture systems, using local HEV strains, should be made.

11. Research gap: Education of the public and health professionals on the transmission pathways of HEV is not implemented in Cuba, Mexico, or Uruguay.

    Recommendation: Information on the hygienic and safe preparation of food and drinking water and specific suggestions for risk groups should be made available to the public, and to health care professionals.

CONCLUSIONS
===========

Given the WHO recommendations for eradicating infectious hepatitis for 2030, joint efforts are needed to assess the disease burden due to HEV in LAC ­countries. As a first step, the symposium described above highlighted research gaps and proposed recommendations for research on and management of HEV infection in Cuba, Mexico, and Uruguay. Given similar demographic, sanitary, and economic conditions in other LAC countries that could predispose them for HEV transmission and infection, these research gaps and recommendations might apply to the entire region. However, future studies are required to determine the distinct needs for handling HEV infections in specific LAC countries.
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